Iron infusion boosts exercise in heart failure
Iron infusion boosts exercise in heart failure
Iron infusion boosts exercise in heart failure
Key points
اہم نکات
मुख्य बातें
- A single iron infusion improved exercise capacity in people with the most common form of heart failure, researchers at Mass General Brigham report.
- In the IRON-MET HFpEF trial, 65 patients with heart failure with preserved ejection fraction and iron deficiency were given either one 1,000-mg intravenous dose of ferric derisomaltose or a placebo.
- After 12 weeks, peak oxygen uptake, a key measure of fitness, rose by about 10% in the iron group and was unchanged in the placebo group.
- A single iron infusion improved exercise capacity in people with the most common form of heart failure, researchers at Mass General Brigham report.
- In the IRON-MET HFpEF trial, 65 patients with heart failure with preserved ejection fraction and iron deficiency were given either one 1,000-mg intravenous dose of ferric derisomaltose or a placebo.
- After 12 weeks, peak oxygen uptake, a key measure of fitness, rose by about 10% in the iron group and was unchanged in the placebo group.
- A single iron infusion improved exercise capacity in people with the most common form of heart failure, researchers at Mass General Brigham report.
- In the IRON-MET HFpEF trial, 65 patients with heart failure with preserved ejection fraction and iron deficiency were given either one 1,000-mg intravenous dose of ferric derisomaltose or a placebo.
- After 12 weeks, peak oxygen uptake, a key measure of fitness, rose by about 10% in the iron group and was unchanged in the placebo group.
A single iron infusion improved exercise capacity in people with the most common form of heart failure, researchers at Mass General Brigham report. In the IRON-MET HFpEF trial, 65 patients with heart failure with preserved ejection fraction and iron deficiency were given either one 1,000-mg intravenous dose of ferric derisomaltose or a placebo. After 12 weeks, peak oxygen uptake, a key measure of fitness, rose by about 10% in the iron group and was unchanged in the placebo group. Walking distance and other exercise measures also improved, though patients' self-reported health scores did not differ significantly. The findings were presented at the American Heart Association Scientific Sessions and published in Circulation. The authors call for larger studies in more diverse patients to see if the benefit lasts.
A single iron infusion improved exercise capacity in people with the most common form of heart failure, researchers at Mass General Brigham report. In the IRON-MET HFpEF trial, 65 patients with heart failure with preserved ejection fraction and iron deficiency were given either one 1,000-mg intravenous dose of ferric derisomaltose or a placebo. After 12 weeks, peak oxygen uptake, a key measure of fitness, rose by about 10% in the iron group and was unchanged in the placebo group. Walking distance and other exercise measures also improved, though patients' self-reported health scores did not differ significantly. The findings were presented at the American Heart Association Scientific Sessions and published in Circulation. The authors call for larger studies in more diverse patients to see if the benefit lasts.
A single iron infusion improved exercise capacity in people with the most common form of heart failure, researchers at Mass General Brigham report. In the IRON-MET HFpEF trial, 65 patients with heart failure with preserved ejection fraction and iron deficiency were given either one 1,000-mg intravenous dose of ferric derisomaltose or a placebo. After 12 weeks, peak oxygen uptake, a key measure of fitness, rose by about 10% in the iron group and was unchanged in the placebo group. Walking distance and other exercise measures also improved, though patients' self-reported health scores did not differ significantly. The findings were presented at the American Heart Association Scientific Sessions and published in Circulation. The authors call for larger studies in more diverse patients to see if the benefit lasts.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।